Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Regul Toxicol Pharmacol ; 57(2-3): 247-55, 2010.
Article in English | MEDLINE | ID: mdl-20233599

ABSTRACT

Melamine (MEL) and cyanuric acid (CYA) may occur simultaneously in milk products. There is no health based guidance value for the mixture of MEL+CYA. Limited toxicological data indicate that MEL+CYA toxicity occurs at levels lower than the toxic doses of the single compounds. The key adverse effect of MEL+CYA is the formation of crystals in the urinary tract, which is dependent on the solubility of the MEL+CYA complex. Urinary concentrations resulting from oral doses of MEL+CYA and MEL alone have been calculated from published data from animal studies. A human exposure scenario assuming consumption of infant formula contaminated at a level of 1 ppm of MEL and CYA each (2 ppm of MEL+CYA) was also analyzed. Margins of more than two orders or magnitude were observed between estimated urine concentrations known to be without detectable effects in rats and calculated human urine concentrations. Because the hazard is related to the physico-chemical characteristics of the mixture, there would be a negligible concern associated with crystal formation if the urinary concentration of the complex is within the solubility range. The solubility of MEL+CYA was higher in urine than in water. A strong pH-dependency was observed with the lowest solubility found at pH 5-5.5. The calculated human urinary concentration was about 30 times less than the solubility limit for MEL+CYA in adult human urine. Altogether, these data provide preliminary evidence suggesting that the presence of 1 ppm of MEL and CYA each in infant formula is unlikely to be of significant health concern.


Subject(s)
Consumer Product Safety , Food Contamination/analysis , Infant Formula/standards , Triazines/urine , Urine/chemistry , Adult , Animals , Female , Humans , Hydrogen-Ion Concentration , In Vitro Techniques , Infant , Infant Formula/chemistry , Male , Middle Aged , Rats , Solubility , Triazines/chemistry , Water/chemistry
2.
Eur J Pharmacol ; 484(1): 41-8, 2004 Jan 19.
Article in English | MEDLINE | ID: mdl-14729380

ABSTRACT

Several antimalarial drugs are known to produce a QT interval prolongation via a blockade of the rapidly activating delayed rectifier K+ current (IKr), encoded by the human-ether-a-go-go-related gene (hERG). We investigated the influence of lumefantrine and its major metabolite desbutyl-lumefantrine, as well as halofantrine, chloroquine, and mefloquine, on wild type hERG K+ channels in stably transfected human embryonic kidney cells (HEK293) using the whole cell patch-clamp technique. All of the tested antimalarial drugs inhibited the hERG K+ channels in a concentration- and time-dependent manner. Only halofantrine blocked hERG tail currents voltage-dependently. The ranking of the half-maximal inhibitory concentrations (IC50) of the antimalarials was: halofantrine (0.04 microM)

Subject(s)
Action Potentials/drug effects , Antimalarials/pharmacology , Potassium Channels, Voltage-Gated , Potassium Channels/physiology , Transfection , Action Potentials/genetics , Antimalarials/chemistry , Cell Line , ERG1 Potassium Channel , Ether-A-Go-Go Potassium Channels , Humans , Potassium Channel Blockers/chemistry , Potassium Channel Blockers/pharmacology , Potassium Channels/genetics , Transfection/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...